Get the Stockscreener App
1,003.57
0.41%
-4.16
After Hours:
1001.99
-1.58
-0.16%
Overview
News
Price History
Option Chain
Financials
Why LLY Down?
Discussions
Forecast
Stock Split
Dividend History
Lilly Eli Co stock is traded at $1,003.57, with a volume of 1.96M.
It is down -0.41% in the last 24 hours and down -9.35% over the past month.
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
See More
Previous Close:
$1,007.73
Open:
$1011.63
24h Volume:
1.96M
Relative Volume:
0.61
Market Cap:
$896.18B
Revenue:
$65.18B
Net Income/Loss:
$20.64B
P/E Ratio:
44.43
EPS:
22.5894
Net Cash Flow:
$5.96B
1W Performance:
-2.46%
1M Performance:
-9.35%
6M Performance:
+35.09%
1Y Performance:
+10.15%
1-Day Range:
$993.66
$1,015.66
1-Week Range:
$993.66
$1,056.20
52-Week Range:
$623.78
$1,133.95
Lilly Eli Co Stock (LLY) Company Profile
Name
Lilly Eli Co
Sector
Industry
Phone
(317) 276-2000
Address
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Compare LLY vs JNJ, ABBV, NVS, AZN
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
1,003.57 | 899.90B | 65.18B | 20.64B | 5.96B | 22.59 |
|
JNJ
Johnson Johnson
|
245.30 | 594.64B | 94.19B | 26.80B | 19.70B | 11.05 |
|
ABBV
Abbvie Inc
|
236.19 | 413.50B | 61.16B | 4.19B | 17.82B | 2.3614 |
|
NVS
Novartis Ag Adr
|
165.15 | 313.28B | 54.72B | 14.02B | 15.32B | 7.1855 |
|
AZN
Astrazeneca Plc
|
201.53 | 312.88B | 58.80B | 10.24B | 8.98B | 3.2788 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-07-26 | Resumed | UBS | Buy |
| Dec-16-25 | Upgrade | Daiwa Securities | Neutral → Buy |
| Dec-15-25 | Reiterated | BofA Securities | Buy |
| Dec-15-25 | Reiterated | Goldman | Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Nov-10-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-20-25 | Reiterated | BMO Capital Markets | Outperform |
| Oct-14-25 | Upgrade | Erste Group | Hold → Buy |
| Sep-17-25 | Downgrade | Berenberg | Buy → Hold |
| Aug-27-25 | Upgrade | HSBC Securities | Reduce → Hold |
| Aug-18-25 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Aug-07-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jun-05-25 | Downgrade | Erste Group | Buy → Hold |
| Apr-28-25 | Downgrade | HSBC Securities | Buy → Reduce |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-24 | Resumed | BofA Securities | Buy |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Sep-13-24 | Resumed | Citigroup | Buy |
| Aug-12-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-21-24 | Downgrade | DZ Bank | Buy → Hold |
| Feb-16-24 | Reiterated | Morgan Stanley | Overweight |
| Dec-21-23 | Downgrade | Daiwa Securities | Buy → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-20-23 | Resumed | UBS | Buy |
| Aug-09-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-26-23 | Reiterated | Citigroup | Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| May-24-23 | Reiterated | BofA Securities | Buy |
| May-24-23 | Reiterated | UBS | Buy |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Feb-15-23 | Downgrade | Societe Generale | Hold → Sell |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Sep-22-22 | Upgrade | UBS | Neutral → Buy |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Mar-10-22 | Initiated | Daiwa Securities | Outperform |
| Jan-21-22 | Upgrade | DZ Bank | Hold → Buy |
| Jan-03-22 | Reiterated | Bernstein | Mkt Perform |
| Dec-17-21 | Initiated | Goldman | Neutral |
| Dec-16-21 | Reiterated | BMO Capital Markets | Outperform |
| Dec-16-21 | Reiterated | BofA Securities | Buy |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Oct-11-21 | Upgrade | Berenberg | Hold → Buy |
| Sep-29-21 | Upgrade | Citigroup | Neutral → Buy |
| Aug-05-21 | Upgrade | DZ Bank | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Jun-24-21 | Reiterated | Cantor Fitzgerald | Overweight |
| Jan-19-21 | Upgrade | Mizuho | Neutral → Buy |
| Dec-10-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Sep-03-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-16-20 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-21-20 | Downgrade | UBS | Buy → Neutral |
| Apr-09-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-06-20 | Initiated | Mizuho | Neutral |
| Dec-18-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| May-28-19 | Initiated | Goldman | Buy |
| Apr-24-19 | Upgrade | Edward Jones | Hold → Buy |
| Apr-11-19 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-12-19 | Initiated | JP Morgan | Overweight |
| Jan-23-19 | Initiated | UBS | Buy |
| Nov-26-18 | Downgrade | Citigroup | Buy → Neutral |
| Oct-31-18 | Upgrade | Credit Suisse | Underperform → Neutral |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Oct-01-18 | Reiterated | SunTrust | Buy |
| Sep-26-18 | Resumed | JP Morgan | Overweight |
View All
Lilly Eli Co Stock (LLY) Latest News
Eli Lilly and Company completed the acquisition of Ventyx Biosciences, Inc. from New Science Ventures, LLC, Affinity Asset Advisors, LLC, The Vanguard Group, Inc., and others. - marketscreener.com
Eli Lilly and booming weight-loss pharma industry now 20% of Irish goods exports - Irish Examiner
Ventyx Biosciences completes $1.2 billion acquisition by Eli Lilly, delists from Nasdaq - Investing.com India
Eli Lilly Unusual Options Activity For March 04 - Benzinga
Richard C. Young & CO. LTD. Makes New $13.88 Million Investment in Eli Lilly and Company $LLY - MarketBeat
Picton Mahoney Asset Management Lowers Holdings in Eli Lilly and Company $LLY - MarketBeat
GLP-1 Receptor Agonist Business Analysis Report 2026: Market to Reach $137.4 Billion by 2030 - GlobeNewswire Inc.
2 Top Growth Stocks to Buy in the First Half of 2026 - AOL.com
Does Lilly’s Broad Pipeline Wins in Obesity and Immunology Reshape the Bull Case for LLY? - simplywall.st
2 Top Growth Stocks to Buy in the First Half of 2026 - The Motley Fool
Eli Lilly and Company (NYSE:LLY) Shares Down 1%Should You Sell? - MarketBeat
Eli Lilly (LLY) Monitored as FDA Targets Telehealth Firms for Mi - GuruFocus
Eli Lilly & Co. stock underperforms Tuesday when compared to competitors - MarketWatch
Eli Lilly and Company $LLY Shares Bought by Victory Capital Management Inc. - MarketBeat
Lilly in the Valley: An Inside Look at Eli Lilly’s Lehigh Valley Investment - Fairfield Sun Times
Eli Lilly and Company $LLY Stock Position Lowered by State Farm Mutual Automobile Insurance Co. - MarketBeat
William Blair Investment Management LLC Lowers Holdings in Eli Lilly and Company $LLY - MarketBeat
South Dakota Investment Council Has $43.08 Million Stock Holdings in Eli Lilly and Company $LLY - MarketBeat
Zepbound (tirzepatide), the most prescribed weight management medication in 2025, now available in multi-dose KwikPen - Eli Lilly and Company
Eli Lilly and Company (NYSE:LLY) Trading Down 3.2%Time to Sell? - MarketBeat
Fisher Asset Management Boosts Eli Lilly Stake - National Today
First Long Island Investors Boosts Eli Lilly Stake - National Today
Tech giants see a cure for cancer in AI. But Eli Lilly’s CEO finds it ‘not particularly good’ at solving biology or chemistry problems - AOL.com
Eli Lilly and Co Stock Closed Down by 3.27% on Mar 2: Facts Behind the Movement - TradingKey
Eli Lilly on track to launch oral obesity drug in second quarter, pending US approval - Reuters
Up Over 400% in 5 Years, Is It Too Late to Invest in Eli Lilly Stock? - AOL.com
Eli Lilly sees a dip — What is pressuring the stock - Traders Union
What Smart Money Loves About Lilly - 24/7 Wall St.
Kingsview Wealth Management LLC Raises Stake in Eli Lilly and Company $LLY - MarketBeat
First Long Island Investors LLC Increases Holdings in Eli Lilly and Company $LLY - MarketBeat
Park Square Financial Group LLC Sells 1,356 Shares of Eli Lilly and Company $LLY - MarketBeat
Geneva Partners LLC Sells 1,884 Shares of Eli Lilly and Company $LLY - MarketBeat
Eli lilly’s $5 billion pharmaceutical plant to boost gooachland and central virginia - Virginia Business
Antibiotics Market - GlobeNewswire Inc.
Aviso Financial Inc. Acquires 1,236 Shares of Eli Lilly and Company $LLY - MarketBeat
How America’s former steel heartland secured a $3.5bn Eli Lilly facility - Pharmaceutical Technology
LLY Stock Price, Quote & Chart | ELI LILLY & CO (NYSE:LLY) - ChartMill
Eli Lilly and Company (NYSE:LLY) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Eli Lilly sticks to premium pricing for its innovator drug ahead of generics wave - The Economic Times
Laurel Wealth Advisors LLC Lowers Stake in Eli Lilly and Company $LLY - MarketBeat
Finemark National Bank & Trust Reduces Stock Position in Eli Lilly and Company $LLY - MarketBeat
Artisan Partners Limited Partnership Grows Stock Position in Eli Lilly and Company $LLY - MarketBeat
Huntington National Bank Has $199.95 Million Holdings in Eli Lilly and Company $LLY - MarketBeat
Ibex Wealth Advisors Sells 5,897 Shares of Eli Lilly and Company $LLY - MarketBeat
Eli Lilly and Company $LLY Shares Bought by Power Wealth Management LLC - MarketBeat
Eli Lilly and Company $LLY Position Boosted by Clal Insurance Enterprises Holdings Ltd - MarketBeat
American Century Companies Inc. Acquires 120,905 Shares of Eli Lilly and Company $LLY - MarketBeat
Eli Lilly begins using ‘mind-blowing’ LillyPod supercomputer at Indy campus - Indiana Economic Digest
Eli Lilly and Company (NYSE:LLY) Trading Up 2.8% Following Analyst Upgrade - MarketBeat
Eli Lilly & Co. stock outperforms competitors on strong trading day - MarketWatch
Eli Lilly Vs. Novo Nordisk: The Valuation Gap Is Unreasonable (NYSE:NVO) - Seeking Alpha
Lilly Eli Co Stock (LLY) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.59%
1.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):